{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-026465","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.758217+00:00","generated_at":"2026-05-15T14:50:23.164767+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"confidence":"high","headline":"Director Julia Haller resigns from Outlook Therapeutics board, effective March 11, 2026","bullets":["Dr. Julia Haller resigned as Class II director, also serving on Nominating and Corporate Governance Committee.","Board accepted resignation on March 6, 2026, effective March 11, with board size reduced to nine.","Resignation not due to any dispute with company; she cited new CEO duties at Wills Eye Hospital.","Company thanked Dr. Haller for her contributions during her tenure."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-026465","json":"https://secwatch.observer/filing/0001104659-26-026465.json","markdown":"https://secwatch.observer/filing/0001104659-26-026465.md","text":"https://secwatch.observer/filing/0001104659-26-026465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926026465/0001104659-26-026465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926026465/tm268371d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:50:23.164767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}